Colorectal Cancer Clinical Trials

38 trials recruiting in Canada.

Cancer

RecruitingDrugDeviceBehavioralOlder adultsHealthy volunteers

23 trials

Comparing 3 approaches for metastatic colorectal cancer

Explore this study →

There are 3 groups in this study. Group A receives Precemtabart tocentecan. Group B receives Bevacizumab, together with one or more of: Precemtabart tocentecan. Group C, the comparison group, receives Trifluridine/Tipiracil (FTD-TPI) and Bevacizumab.

Sites in Ottawa, Toronto and 1 more city

  • Phase 3
  • 3 groups
  • Sites in Vancouver, Ottawa and 1 more city
  • Recruiting

Official title: A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic Colorectal Cancer · EMD Serono Research & Development Institute, Inc.

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for colorectal cancer.

Comparing Stereotactic Ablative Radiotherapy with Chemotherapy for metastatic colorectal adenocarcinoma

Explore this study →

There are 2 groups in this study. Group A receives Chemotherapy, together with one or more of: Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Computed Tomography, Magnetic Resonance Imaging and Positron Emission Tomography. Group B, the comparison group, receives Chemotherapy, together with one or more of: Computed Tomography, Magnetic Resonance Imaging and Positron Emission Tomography.

One site, in Calgary

  • Phase 2
  • 2 groups
  • One site, in Calgary
  • Recruiting

Official title: Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Metastatic Colorectal Adenocarcinoma · Alliance for Clinical Trials in Oncology

Comparing Amivantamab with Cetuximab for colorectal neoplasms

Explore this study →

There are 2 groups in this study. Group A receives Amivantamab, together with one or more of: 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin and Irinotecan Hydrochloride. Group B, the comparison group, receives Cetuximab, together with one or more of: 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin and Irinotecan Hydrochloride.

Sites in Calgary, Montreal and 2 more cities

  • Phase 3
  • 2 groups
  • Sites in Calgary, Ottawa and 2 more cities
  • Recruiting

Official title: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms · Janssen Research & Development, LLC

Comparing 3 approaches for colorectal cancer

Explore this study →

There are 3 groups in this study. Group A receives Sacituzumab tirumotecan, together with one or more of: Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication and Supportive care measures. Group B receives Sacituzumab tirumotecan, together with one or more of: Rescue medication and Supportive care measures. Group C receives Sacituzumab tirumotecan, Cisplatin and Pembrolizumab, together with one or more of: Rescue medication and Supportive care measures.

Sites in Montreal and Ottawa

  • Phase 1
  • 3 groups
  • Sites in Ottawa and Montreal
  • Recruiting

Official title: A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Colorectal Cancer · Merck Sharp & Dohme LLC

Comparing 8 approaches for metastatic colorectal cancer

Explore this study →

There are 8 groups in this study. Groups A, B and C receive Telisotuzumab Adizutecan, together with one or more of: Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab. Group D receives one or more of: Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab. Groups E, F and G receive Telisotuzumab Adizutecan, together with one or more of: Fluorouracil, Leucovorin and Panitumumab. …and 1 more groups.

Sites in Calgary, Edmonton and 3 more cities

  • Phase 2
  • 8 groups
  • Sites in Calgary, Edmonton and 3 more cities
  • Recruiting

Official title: A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer · AbbVie

Comparing 5 approaches for untreated, unresectable, or metastatic colorectal cancer

Explore this study →

There are 5 groups in this study. Groups A and B receive one or more of: Pumitamig, FOLFOX and FOLFIRI. Group C receives one or more of: FOLFOX, FOLFIRI and Bevacizumab. Group D receives one or more of: Pumitamig, FOLFOX, FOLFIRI and CAPOX. …and 1 more groups.

Sites in Montreal, Toronto and 4 more cities

  • Phase 2
  • 5 groups
  • Sites in Calgary, Halifax and 4 more cities
  • Recruiting

Official title: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Untreated, Unresectable, or Metastatic Colorectal Cancer · Bristol-Myers Squibb

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Colorectal Cancer trials near you.

Colorectal Cancer
Want matched now instead? →
← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.